Business
Govt Aims To Boost Domestic Pulses Output To 350 Lakh Tonnes By 2030–31
New Delhi: Prime Minister Narendra Modi on Saturday launched the ‘Mission for Aatmanirbharta in Pulses’ (2025–26 to 2030–31), a major step toward boosting India’s self-reliance in food production. With a budget of Rs 11,440 crore, the mission aims to increase domestic pulses production to 350 lakh tonnes and expand the cultivation area to 310 lakh hectares by 2030–31, strengthening India’s agricultural foundation and reducing import dependence.
Nearly 2 Crore Farmers to Benefit from the Pulses Mission
According to an official statement, around 2 crore farmers are set to benefit from assured procurement, quality seed distribution, and stronger value chain support under the new mission. India’s pulses sector has already seen remarkable progress over the years—thanks to sustained government efforts under the National Food Security and Nutrition Mission (NFSNM). Pulses production has surged from 192.6 lakh tonnes in 2013–14 to 252.38 lakh tonnes in 2024–25 (third advance estimates), marking an impressive 31 per cent growth.
India Still Relies on Imports Despite Rising Pulses Output
While India’s progress in pulses production is impressive, there is still huge potential to boost output and meet the country’s growing consumption needs. In 2023–24, India imported 47.38 lakh tonnes of pulses and exported 5.94 lakh tonnes, underscoring the need for further structural improvements. Despite being one of the world’s largest producers of pulses, domestic production still falls short of demand—making imports an important supplement.
With pulses imports reaching 47.38 lakh tonnes in 2023–24, the government has prioritised achieving self-sufficiency in pulses as a key national objective, the statement added. Beyond their economic and trade significance, pulses serve as a nutritional powerhouse. As per the National Institute of Nutrition, they contribute nearly 20-25 per cent of total protein intake in Indian diets.
However, the per capita consumption of pulses continues to fall short of the recommended 85 grams per day, contributing to protein-energy malnutrition across the country. Therefore, enhancing domestic production is not only an economic necessity but also a vital step toward improving public health.
Recognizing this dual importance, the government has placed strong emphasis on strengthening the pulses sector. The ‘Mission for Aatmanirbharta in Pulses’ was announced in the Union Budget 2025–26 and was approved by the Union Cabinet on October 1 2025.
It seeks to boost domestic production, reduce import dependence, and pave the way for an “Aatmanirbhar Bharat” in pulses. To ensure effective implementation, states will prepare rolling five-year seed production plans, with breeder seed production monitored by ICAR and quality assurance maintained through the SATHI portal. (With IANS Inputs)
Business
FDA vaccine head will step down in April after string of controversial decisions
The logo for the Food and Drug Administration is seen ahead of a news conference at the Health and Human Services Headquarters in Washington, April 22, 2025.
Nathan Posner | Anadolu | Getty Images
A key U.S. Food and Drug Administration official who oversees vaccines and biotech treatments will step down from the agency following multiple decisions that raised concerns within the industry.
Vinay Prasad, director of the Center for Biologics Evaluation and Research, will leave the FDA at the end of April, an agency spokesperson confirmed on Friday. It is his second departure from the position: He briefly left the post in July following backlash over his regulatory decisions, and returned only two weeks later in August.
In a post on X, FDA Commissioner Marty Makary said the FDA will appoint a successor before Prasad returns next month to the University of California San Francisco, where he taught before taking the FDA position last year. Makary said Prasad “got a tremendous amount accomplished” during his tenure at the agency.
Prasad’s decision to step down comes after criticism of the FDA mounted within the biotech and pharmaceutical industry and among former health officials. In the past year, the agency has denied or discouraged the approval applications of at least eight drugs, according to RTW Investments, after taking issue with data the companies used to support their applications. The FDA also initially refused to review Moderna’s flu shot before it later reversed course.
All of those companies accused the FDA of reversing previous guidance about the evidence they could use to back their applications, sparking criticism within the industry that an unreliable regulatory process could stifle development of drugs for hard-to-treat diseases.
A former FDA official who spoke to CNBC on the condition of anonymity to speak freely on the issue called the reversals the worst kind of regulatory uncertainty because companies say they are being told one thing and then experience another.
In a statement earlier Friday, an FDA spokesperson said there was “no regulatory uncertainty,” adding the agency “makes decisions based on the evidence, but does not make assurances about outcomes.” The spokesperson said the FDA is “conducting rigorous, independent reviews and not rubber-stamping approvals.”
The most recent controversy came after the FDA discouraged UniQure from applying for expedited approval of its experimental treatment for Huntington’s disease.
The agency, which underwent staff cuts and an overhaul under Health and Human Services Secretary Robert F. Kennedy Jr., has faced broader backlash for its drug and vaccine approvals process. Critics have worried the agency could stifle the development of new treatments and risk the safety of patients.
The Wall Street Journal earlier reported Prasad’s departure.
Business
Oil price at two-year high after Qatar minister warns all Gulf production could stop
Energy Minister Saad al-Kaabi says oil could hit $150 a barrel if the Iran conflict continues over the coming weeks.
Source link
Business
Govt increases petrol, diesel prices by Rs55 per litre amid Middle East tensions – SUCH TV
The federal government has raised petrol prices by Rs55 per litre as surging global oil prices, fuelled by the US‑Israel war with Iran, put pressure on domestic energy costs.
The announcement was made by Petroleum Minister Ali Pervaiz Malik in a press conference alongside DPM Ishar Dar and Finance Minister Muhammad Aurangzeb.
This marks the first weekly review of fuel prices since regional tensions threatened a major share of global energy flows following the closure of the Strait of Hormuz.
Previously, the federal government adjusted petroleum prices on a fortnightly basis.
-
Business1 week agoAttock Cement’s acquisition approved | The Express Tribune
-
Fashion1 week agoPolicy easing drives Argentina’s garment import surge in 2025
-
Business1 week agoIndia Us Trade Deal: Fresh look at India-US trade deal? May be ‘rebalanced’ if circumstances change, says Piyush Goyal – The Times of India
-
Politics1 week agoUS arrests ex-Air Force pilot for ‘training’ Chinese military
-
Entertainment1 week agoBobby J. Brown, “The Wire” and “Law & Order: SUV” actor, dies of smoke inhalation after reported fire
-
Sports1 week agoLPGA legend shares her feelings about US women’s Olympic wins: ‘Gets me really emotional’
-
Fashion7 days agoSouth Korea’s Misto Holdings completes planned leadership transition
-
Politics1 week agoWhat are Iran’s ballistic missile capabilities?
